Clinical Trials Search Results
Results 31-40 of 416 for your search
Show Search Criteria
Your Search Criteria
Category |
Your Selection |
|---|---|
| Keywords/Phrases: | melanoma |
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Status: Active
Age: 12 years and over
Gender: Male or Female
Location: 13 locations
Age: 12 years and over
Gender: Male or Female
Location: 13 locations
Pembrolizumab and Ipilimumab in Treating Patients with Previously Treated Advanced Melanoma
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed / Refractory Synovial Sarcoma
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 12 locations
Age: 18 years and over
Gender: Male or Female
Location: 12 locations
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 9 locations
Age: 18 years and over
Gender: Male or Female
Location: 9 locations
Cabozantinib S-malate and Cetuximab in Treating Patients with Metastatic Head and Neck Squamous Cell Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 9 locations
Age: 18 years and over
Gender: Male or Female
Location: 9 locations
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 9 locations
Age: 18 years and over
Gender: Male or Female
Location: 9 locations
Adjuvant Avelumab in Merkel Cell Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
QUILT-3.055: A Study of ALT-803 in Combination With PD-1 / PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 9 locations
Age: 18 years and over
Gender: Male or Female
Location: 9 locations